Response of early active rheumatoid arthritis to tumor necrosis factor inhibitors: evaluation by magnetic resonance imaging

References

• Ostegaard M, Hansen M, Stoltenberg M, Jensen KE, Szkudlarek M, Pedersen-Zbinden B, et al. New radiographic bone erosions in the wrists of patients with rheumatoid arthritis are detectable with magnetic resonance imaging a median of two years earlier. Arthritis Rheum. 2003;48:2128–31.
   Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.
   PubMed Web of Science ®Google Scholar
• Sharp JT, Young DY, Bluhm GB, Brower AC, Corbett M, et al. How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis? Arthritis Rheum. 1985;28:1326–35.
   Google Scholar
• Plant MJ, Saldatvala J, Borg AA, Jones PW, Dawes PT. Mea-surement and prediction of radiological progression in early rheumatoid arthritis. J Rheumatol. 1994;21:1808–13.
   Google Scholar
• Ostergaard M, Edmonds J, McQeen F, Peterfy C, Lassere M, Ejbjerg B, et al. An introduction to the EULAR-OMERACT rheumatoid arthritis MRI reference image atlas. Ann Rheum Dis. 2005;64(Suppl 1):i3–i7.
   Google Scholar
• Cohen J. Statistical power analysis for the behavioral sciences. 2nd edn. Hillsdale: Lawrence Erlbaum; 1988.
   Google Scholar
• Koike R, Takeuchi T, Eguchi K, Miyasaka N. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol. 2007;17:451–8.
   PubMedGoogle Scholar
• Revised guidelines for TNF inhibitor therapy (published in January 2008). Tokyo: Japan College of Rheumatology
   Google Scholar
• Smyth CJ. Therapy of rheumatoid arthritis. A pyramidal plan. Postgrad Med. 1972;51:31–9.
   PubMed Web of Science ®Google Scholar
• Weinblat ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med. 1985;312:818–22.
   PubMedGoogle Scholar
• Williams H.T, Willkens RF, Samuelson CO Jr, Alarcon GA, Guttadauria M, Yarboro C, et al. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. Arthritis Rheum. 1985;28:721–30.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt K, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheu-matoid arthritis receiving methotrexate. N Engl J Med. 1999;340:253–9.
   PubMed Web of Science ®Google Scholar
• Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor monoclonal antibody) versus placebo in rheumatoid arthritis receiving concomitant methotrexate: a randomized phase III trial. Lancet. 1999;354:1932–9.
   PubMed Web of Science ®Google Scholar
• Klareskog L, van der Heijde D, Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of eta-nercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blinded randomised controlled trial. Lancet. 2004;363:675–81.
   PubMed Web of Science ®Google Scholar
• St. Clair EW, van der Heijde DMFM, Smolen JF, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis. Arthritis Rheum. 2004;50:3432–43.
   PubMed Web of Science ®Google Scholar
• Brown AK, Quinn MA, Karim Z, Conaghan PG, Peterfy CG, Hensor E, et al. Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission. Arthritis Rheum. 2006;54:3761–73.
   PubMed Web of Science ®Google Scholar
• Gaylis NB, Needell SD, Rudensky D. Comparison of in-office magnetic resonance imaging versus conventional radiography in detecting changes in erosions after one year of infliximab therapy in patients with rheumatoid arthritis. Mod Rheumatol. 2007; 17:273–8.
   Google Scholar
• Bathon JM, Martin RW, Fleishmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000;343 :1586–93.
   PubMed Web of Science ®Google Scholar
• Nell VPK, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology. 2004;43:906–14.
   PubMed Web of Science ®Google Scholar
• Schirmer C, Scheel AK, Althoff CE, Schink T, Eshed I, Lembcke A, et al. Diagnostic quality and scoring of synovitis, tenosynovitis and erosions in low-field MRI of patients with rheumatoid arthritis: a comparison with conventional MRI. Ann Rheum Dis. 2007;66:522–9.
   PubMed Web of Science ®Google Scholar
• Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal. Results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52:27–35.
   Google Scholar
• Martinez-Martinez MU, Cuevas-Orta E, Reyes-Vaca G, Baranda L, Gonzalez-Amaro R, and Abud-Mendoza. Magnetic resonance imaging in patients with rheumatoid arthritis with complete remission treated with disease-modifying antirheumatic drugs or anti-tumour necrosis factor a agents: Ann Rheum Dis 2007;66: 134–5.
   Google Scholar
• Conaghan PG, McQeen FM, Peterfy CG, Lassere MND, Ejbjerg B, Bird P, et al. The evidence for magnetic resonance imaging as an outcome measure in proof-of-concept rheumatoid arthritis studies. J Rheumatol. 2005;32:2465–9.
   PubMedGoogle Scholar